SCHEMBL6402014

SCHEMBL6402014

O=P(O)(O)Sc1ccc(O)cc1C(O)CCCc1ccc(O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.36
ALOX15 P16050 1/20 0.36
SLC28A3 Q9HAS3 1/20 0.35
AKR1B10 O60218 2/20 0.34
AKR1B1 P15121 2/20 0.34
TRPV1 Q8NER1 1/20 0.34
AKR1A1 P14550 1/20 0.34
CBR1 P16152 1/20 0.34
AKR1C4 P17516 1/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
ESR1 P03372 3/20 0.33
ADRA2A P08913 2/20 0.33
ADORA3 P0DMS8 2/20 0.33
TACR2 P21452 2/20 0.33
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6399201 0.93 ADRB2 (0.35) ESR1ESR2ADRB2
SCHEMBL6398858 0.90 IGF1R (0.36) IGF1RALOX15SLC28A3AKR1B10AKR1B1
SCHEMBL6402235 0.89 MGLL (0.39) AKR1B10AKR1B1ADRB2
SCHEMBL6402674 0.86 SLC7A5 (0.35) ESR1ADORA3SLC6A2SLC6A4SLC6A3
SCHEMBL6401423 0.83 ADRB2 (0.35) ESR1ESR2ADRB2
SCHEMBL6395856 0.82 ANPEP (0.41) CHRM2CHRM1CHRM3ADRB2
SCHEMBL6402018 0.80 IGF1R (0.38) IGF1RALOX15SLC28A3TRPV1ESR1
SCHEMBL6402793 0.80 SLC28A3 (0.42) IGF1RALOX15SLC28A3TRPV1ESR1
SCHEMBL6403040 0.79 MGLL (0.39) AKR1B10AKR1B1CHRM2CHRM1CHRM3
SCHEMBL6399251 0.78 IGF1R (0.42) IGF1RALOX15SLC28A3AKR1B10AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 IGF1R 1022/4885ALOX15 2521/4885SLC28A3 48/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 IGF1R 1132/4885ALOX15 2491/4885SLC28A3 47/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 IGF1R 1022/4885ALOX15 2521/4885SLC28A3 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.